ID   MR10-1
AC   CVCL_U181
DR   CLO; CLO_0050917
DR   RCB; RCB0507
DR   Wikidata; Q54906569
RX   PubMed=2372878;
RX   PubMed=3163531;
RX   PubMed=3608093;
CC   Population: African American.
CC   Selected for resistance to: ChEBI; CHEBI:21759; N-methyl-N'-nitro-N-nitrosoguanidine (MNNG).
CC   Transformant: NCBI_TaxID; 333761; Human papillomavirus type 18 (HPV18).
CC   Derived from site: In situ; Uterus, cervix; UBERON=UBERON_0000002.
ST   Source(s): RCB
ST   Amelogenin: X
ST   CSF1PO: 9,10
ST   D16S539: 9,10
ST   D5S818: 11,12
ST   D7S820: 8
ST   TH01: 7
ST   TPOX: 8,12
ST   vWA: 15,18
DI   NCIt; C27677; Human papillomavirus-related cervical adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_U209 ! HeLa S3 mer-
SX   Female
AG   30Y6M
CA   Cancer cell line
DT   Created: 03-02-14; Last updated: 05-10-23; Version: 13
//
RX   PubMed=2372878; DOI=10.1093/carcin/11.7.1209;
RA   Ishida R., Utsumi K.R.;
RT   "Differences in induction of sister chromatid exchanges in MNNG-resistant
RT   HeLa S3 Mer- cell lines.";
RL   Carcinogenesis 11:1209-1212(1990).
//
RX   PubMed=3163531; DOI=10.1093/carcin/9.6.1079;
RA   Ishida R., Takahashi T.;
RT   "Increased O6-methylguanine-DNA methyltransferase activity and reduced
RT   mutability in 1-(4-amino-2-methyl-5-pyrimidinyl)methyl-3-(2-chloroethyl)
RT   3-nitrosourea-resistant HeLa S3 cells.";
RL   Carcinogenesis 9:1079-1083(1988).
//
RX   PubMed=3608093; DOI=10.1093/carcin/8.8.1109;
RA   Ishida R., Takahashi T.;
RT   "N-methyl-N'-nitro-N-nitrosoguanidine-resistant HeLa S3 cells still
RT   have little O6-methylguanine-DNA methyltransferase activity and are
RT   hypermutable by alkylating agents.";
RL   Carcinogenesis 8:1109-1113(1987).
//